← Human Trials & Peer-Reviewed Studies
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators
Plain-language guide to PMID 10755201 (2000): double-blind randomized controlled trial study of Angiotensin II in 08 patients.
Key Facts
- PMID
- 10755201
- Journal
- Cardiovascular drugs and therapy
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Oosterga M et al. (10 authors)
- DOI
- 10.1023/a:1007843205311
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature.
Why It Was Studied
Patients (n = 187) scheduled for coronary artery bypass surgery used study medication 27 +/- 1 days before surgery.
Who Took Part
The study group was 08 patients.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, single-blind and placebo-controlled study.
Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the patients and researchers unaware of who received Angiotensin II.
In this single-blind Angiotensin II study one party knew the assignments and the other did not.
A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Angiotensin I, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Cardiovascular Diseases, Coronary Artery Bypass and Renin-Angiotensin System.
What This Means in Plain Language
The paper is a randomized, double-blind and single-blind study of Angiotensin II in 08 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2000 (Cardiovascular drugs and therapy), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.